Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v30i17.2892

THE HIDDEN CONNECTION: UNVEILING THE LINK BETWEEN BREAST CANCER AND METABOLIC SYNDROME

Ryad Moftah Alati[1]*, Dr Padmini Sahu[2], Dr Muralidhar Panigrahi[3], Dr. Aishwarya Arunkumar Kamble[4], Dr Yajnesh Prasanna Sahu[5], Dr Seema Yadav[6]

[1*]Al asmarya Islamic University, Email: Ry.alati@asmsrya.edu.ly
[2]Assistant Professor, General Medicine, Bhima Bhoi Medical College Balangir
Email: drpdmnsahu@gmail.com
[3]Associate Professor, Pharmacology, Bhima Bhoi Medical College Balangir
Email: mdpanigrahi@gmail.com
[4]MD Internal Medicine Physician Email: aishwaryaarunkumar67@gmail.com
[5]Assistant Professor, Pharmacology, Bhima Bhoi Medical College, Balangir,
drypsahu@gmail.com
[6]Principal College of Nursing. Sarojini Naidu Medical College Agra,UP.
Email: Seemakishan22@ gmail.com

***Corresponding Author: -** Ryad Moftah Alati
[*]Al asmarya Islamic University, Email: Ry.alati@asmsrya.edu.ly

Abstract: -
In today's fast-paced and convenience-driven world, metabolic syndrome has become a growing concern. Not only does it increase the risk of heart disease, diabetes, and stroke, but recent research suggests that it may also be linked to an increased risk of breast cancer. Unraveling the connection between metabolic syndrome and breast cancer is an important step in understanding this complex disease and potentially finding new ways to prevent or treat it. Recent investigation has suggested a plausible connection between MS and breast tumorigenesis, encompassing diverse hormonal pathways like insulin, estrogen, cytokines, and growth factors. This investigation sought to gauge the frequency of metabolic syndrome in breast cancer patients and evaluate its function as a separate risk factor for breast cancer occurrence. A group of breast cancer patients and controls was examined for the occurrence of MS and its constituents, unveiling a noteworthy correlation between metabolic syndrome and breast cancer hazard. Researchers suspect that the underlying mechanisms of metabolic syndromes, such as chronic inflammation and hormonal imbalances, may play a role in the development and progression of breast cancer.

Keywords Cancer, chronic, metabolic, obesity, syndrome, tumor

Introduction

Breast cancer indeed has a high incidence among women globally. Its occurrence can be influenced by a combination of genetic, hormonal, and environmental factors. Hormones like estrogen and progesterone can contribute to the growth of some types of breast cancer. Factors related to reproduction, such as early age at first menstruation (early menarche), late age at menopause, and not having children or having them at a later age, can impact hormone exposure and affect breast cancer risk. Environmental factors are also thought to contribute to breast cancer risk(1-4). These can include

exposure to certain chemicals, pollutants, and lifestyle factors. A high-fat diet, for instance, has been associated with increased estrogen levels in the body, which could potentially contribute to breast cancer development. Postmenopausal weight gain can lead to increased levels of estrogen in the body due to fat cells being a source of estrogen production. Reduced physical activity, a diet rich in fats and refined carbohydrates, along with high consumption of animal protein—are believed to contribute to the development of metabolic syndrome. The prevalence of obesity, which is a key component of MetS, has been rising globally over recent decades. This increase in obesity rates has been linked to changes in dietary habits, decreased physical activity levels, and other environmental and societal factors. Statistical data you provide the increasing prevalence of obesity and the projected proportions by 2030, these numbers underline the urgency of addressing the global obesity epidemic and its potential impact on various health conditions, including breast cancer (7). Public health efforts to promote healthy lifestyles, improve dietary habits, and encourage regular physical activity are crucial in mitigating the risks associated with metabolic syndrome and obesity-related diseases. It is a collection of conditions that occur together, increasing the risk of various health problems. In this extensive guide, we will explore the present condition of understanding concerning the connection between breast cancer and metabolic syndrome. We will investigate the fundamental biological mechanisms linking these two apparently separate entities and deliberate on the possible consequences of lifestyle factors, hereditary traits, and endocrine influences (8). Furthermore, we will scrutinize the most recent investigation discoveries and emphasize pivotal insights to equip readers with indispensable wisdom to make enlightened determinations about their health and well-being. By means of this expedition, we aspire to elevate consciousness regarding the conceivable consequences of metabolic syndrome in breast cancer susceptibility and motivate additional investigation to progress our comprehension of this intricate correlation. Equipped with this understanding, individuals and healthcare practitioners can collaborate to establish tailored prevention and intervention approaches, ultimately contributing to a future with diminished breast cancer load and enhanced overall health results. (9) Since breast cancer is influenced by hormonal factors, it's important to consider how risk factors might affect women differently based on their menopausal status. Each of these conditions independently poses a threat to one's health, but when combined, they become a potent risk factor for cardiovascular diseases, diabetes, and now, even breast cancer. The underlying cause of metabolic syndrome is still not entirely understood, but there are several risk factors that contribute to its development. A sedentary lifestyle, poor diet, obesity, and genetics all play a role in the onset of metabolic syndrome. Additionally, When insulin resistance occurs, the body needs to produce higher amounts of insulin to keep blood sugar levels in check (10-13). This can lead to a variety of health issues, especially when it becomes chronic. The connection between insulin resistance and various metabolic disorders, including type 2 diabetes, is well-established. The connection between insulin resistance and breast cancer is complex, and there is ongoing research in this area. Some studies suggest that there might be a link between insulin resistance and an increased risk of breast cancer. Insulin is known to stimulate the growth of certain cells, and if the body is resistant to its effects, it could potentially create an environment that promotes the growth of cancer cells.

Investigating the Connection Between Metabolic Syndrome and Breast Cancer

Recent studies have shed light on the potential link between metabolic syndrome and breast cancer. While the connection is still being unraveled, researchers have observed that women with metabolic syndrome have an elevated likelihood of developing breast cancer in contrast to those without the syndrome (14). This link holds true even after accounting for other risk factors, such as age, family history, and hormone replacement therapy. One of the key mechanisms through which metabolic syndrome may increase the risk of breast cancer is through insulin resistance. Insulin is a hormone that regulates blood sugar levels, and when cells become resistant to its effects, the body compensates by producing more insulin. Additionally, insulin-like growth factor 1 (IGF-1), which is regulated by insulin, has been implicated in breast cancer development. While they are distinct conditions, there is emerging evidence suggesting a potential link between metabolic syndrome and an elevated

susceptibility to developing breast cancer however, it's important to note that the relationship between these two conditions is still being studied, and the exact mechanisms and interactions are not fully understood (15-18). Metabolic syndrome is a cluster of interconnected metabolic risk factors that often occur together and increase the risk of various health issues, including cardiovascular disease and type 2 diabetes. The main components of metabolic syndrome typically include:

- *Obesity*: Excess body fat, particularly abdominal fat.
- *Insulin* Resistance: Cells become less responsive to the effects of insulin, leading to higher blood sugar levels.
- *High Blood Pressure*: Elevated blood pressure levels.
- *Dyslipidemia*: Abnormal levels of cholesterol and triglycerides in the blood.

It's influenced by a combination of genetic, hormonal, environmental, and lifestyle factors. Metabolic syndrome can be associated with alterations in hormone levels, including insulin and sex hormones like estrogen. Elevated insulin levels and insulin resistance, common in metabolic syndrome, can lead to higher levels of circulating insulin-like growth factors (IGFs) and estrogen, which might contribute to breast cancer development. The syndrome often involves chronic low-grade inflammation. Inflammation is thought to play a role in cancer development and progression. Elevated levels of inflammatory markers could potentially promote the growth of cancer cells. Excess fat tissue, particularly abdominal fat, is a hallmark of metabolic syndrome. Adipose tissue produces various signaling molecules, including hormones and cytokines, that can influence cancer development. Increased fat tissue might contribute to an environment conducive to cancer growth. Insulin resistance and elevated insulin levels can lead to higher levels of IGFs. IGFs are known to promote cell growth and division, and their overactivity has been associated with various cancers, including breast cancer. Both metabolic syndrome and breast cancer risk share certain lifestyle factors, such as poor diet, lack of physical activity, and obesity. These factors can contribute to the development of both conditions. A potential link between metabolic syndrome and breast cancer, not all individuals with metabolic syndrome will develop breast cancer, and not all breast cancer cases are linked to metabolic syndrome. Genetics, individual variations, and other factors also play crucial roles. Researchers are actively investigating the complex interactions between metabolic syndrome and breast cancer to better understand the underlying mechanisms and develop targeted prevention and treatment strategies(19-22).



Flow diagram of Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses



Flow diagram of Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses

Risk factors for developing metabolic syndrome

Several risk factors contribute to the development of metabolic syndrome. A sedentary lifestyle, poor diet, and obesity are among the primary factors. Genetic factors also play a role, as some individuals may be more predisposed to developing metabolic disorders. Age is another risk factor, as metabolic syndrome becomes more prevalent with age. Hormonal changes during menopause can also contribute to the development of metabolic syndrome in women. Excess weight, especially abdominal fat, is a major risk factor. A sedentary lifestyle contributes to obesity and insulin resistance, both of which are key components of metabolic syndrome. If your parents or close relatives have a history of diabetes, obesity, or heart disease, you might be at a higher risk(23). Hormonal changes and a decrease in physical activity can contribute to this risk. Conditions such as polycystic ovary syndrome (PCOS) and hormonal disorders can contribute to metabolic syndrome. Smoking can contribute to insulin resistance and increase the risk of other cardiovascular problems. Sleep apnea is associated with obesity and can contribute to insulin resistance and metabolic abnormalities. Chronic stress can influence hormones and behaviors that contribute to metabolic syndrome, such as overeating and lack of exercise. Conditions like fatty liver disease, chronic kidney disease, and certain hormonal disorders can increase the risk of metabolic syndrome. Lifestyle changes, such as maintaining a healthy weight, engaging in regular physical activity, and adopting a balanced and nutritious diet, can help reduce the risk and even reverse some of the factors associated with metabolic syndrome (24-26).

Risk factors for developing breast cancer

Breast cancer is the most common cancer among women worldwide, and several risk factors contribute to its development. Age is one of the primary risk factors, with the risk increasing as women get older. Genetic mutations, such as BRCA1 and BRCA2 gene mutations, are associated with a significantly higher risk of developing breast cancer. Other risk factors for breast cancer include hormonal factors, such as early onset of menstruation, late onset of menopause, and hormone replacement therapy. Obesity, particularly after menopause, is another significant risk factor for breast cancer (27).

The role of insulin resistance in metabolic syndrome and breast cancer

These elevated insulin levels can promote the growth of cancer cells, including breast cancer cells. Breast cancer cells often express insulin receptors, allowing them to respond to the growth-promoting effects of insulin. In addition to directly promoting the growth of cancer cells, insulin resistance is also associated with other metabolic changes that may contribute to breast cancer development, such

as increased inflammation and hormonal imbalances (28-31). This leads to an increased demand for insulin production by the pancreas, eventually resulting in high blood sugar levels (hyperglycemia). Metabolic syndrome is typically characterized by a combination of the following factors:

- ✓ Excess fat around the waist.
- ✓ Elevated blood sugar levels and reduced sensitivity to insulin.
- ✓ Abnormal levels of cholesterol and triglycerides in the blood.
- ✓ High blood pressure.
- ✓ Increased levels of inflammatory markers and factors that promote blood clotting.
- ✓ *Hormonal Environment*: Insulin resistance and hyperinsulinemia (high insulin levels) can lead to an increase in the production of insulin-like growth factor 1 (IGF-1). IGF-1 has been associated with cell growth, proliferation, and survival, and higher levels of IGF-1 have been linked to an increased risk of breast cancer.
- ✓ *Inflammation*: Insulin resistance and obesity are often accompanied by chronic low-grade inflammation. Inflammation can contribute to cancer development by promoting DNA damage, cell proliferation, and tissue remodeling. Inflammatory factors may play a role in breast cancer initiation and progression.
- ✓ *Adipokines*: Adipokines are hormones released by fat cells. In conditions of obesity and insulin resistance, abnormal adipokine levels can contribute to cancer growth. Leptin, an adipokine associated with obesity, has been shown to promote breast cancer cell proliferation and migration.
- ✓ *Estrogen Levels*: Adipose tissue (fat cells) is involved in the production of estrogen through the conversion of androgens to estrogens. Higher levels of adipose tissue in obesity can lead to increased estrogen production. Estrogen exposure is a known risk factor for hormone receptor-positive breast cancers.
- ✓ *Insulin-Like Growth Factors*: As mentioned earlier, insulin resistance can lead to increased levels of IGF-1, which can stimulate cell growth and inhibit apoptosis (programmed cell death). These processes can contribute to the development and progression of cancer.

More studies are needed to fully understand the underlying mechanisms and to develop targeted strategies for prevention and treatment. Metabolic syndrome is characterized by insulin resistance, which leads to increased insulin levels in the bloodstream (hyperinsulinemia). This hyperinsulinemia contributes to breast cancer risk by affecting the bioavailability of insulin-like growth factor 1 (IGF-1). Insulin resistance inhibits the liver's production of IGF-binding proteins, thereby increasing the levels of free IGF-1. Both insulin and IGF-1 are known to promote cell growth and inhibit cell death, making them potentially harmful in terms of breast cancer risk. Hyperinsulinemia stimulates the expression of growth hormone receptors (GHR) in the liver. This can potentially enhance liver production of IGF-1 through enhanced GHR signaling. Elevated IGF-1 levels, in combination with insulin, can further contribute to the mitogenic and anti-apoptotic effects on breast epithelial cells and breast cancer cells. Insulin can influence breast cancer risk by affecting hormone levels. In postmenopausal women, insulin increases the production of androgens (male sex hormones) by the ovaries. These androgens are then converted to estrogens in peripheral tissues, which becomes a significant source of estrogen after menopause. Inflammation in the breast tissue can create a microenvironment that supports tumor cell proliferation. Leptin, a hormone produced by fat cells, can stimulate cell growth, and play a role in breast cancer progression. Reduced levels of adiponectin, another hormone produced by fat cells, are characteristic of metabolic syndrome. Adiponectin has anti-proliferative and pro-apoptotic effects on tumor cells. Its decreased levels in metabolic syndrome may contribute to a lack of regulation of tumor cell proliferation and inhibition of cell death. This complex interplay of factors highlights how metabolic syndrome, characterized by insulin resistance and related metabolic disturbances, can influence breast cancer risk in postmenopausal women through various interconnected mechanisms involving hormones, growth factors, and inflammatory molecules (32-35).

Inflammation and its impact on metabolic syndrome and breast cancer

Tumor-associated inflammation has been shown to promote the growth and spread of cancer cells. Inflammatory cells produce cytokines and growth factors that create a favorable environment for tumor growth. Additionally, chronic inflammation can cause DNA damage and impair the body's immune response to cancer cells, further facilitating tumor development. Inflammation has been linked to breast cancer development and progression through several mechanisms.

- ✓ *Tumor Microenvironment***:** Inflammation can create a pro-tumorigenic microenvironment in breast tissue. Immune cells, such as macrophages, can infiltrate the tumor site and release inflammatory cytokines, growth factors, and enzymes that promote tumor growth, invasion, and angiogenesis (formation of new blood vessels to supply the tumor).
- ✓ *Genetic Mutations***:** Inflammatory processes can cause DNA damage and mutations in cells. Chronic inflammation can increase the risk of genetic alterations that contribute to the development of cancer.
- ✓ *Hormone Regulation***:** Inflammatory pathways can impact the production and metabolism of hormones such as estrogen, which plays a crucial role in some forms of breast cancer. Inflammatory molecules can interact with hormone receptors and promote the growth of hormone-sensitive tumors.
- ✓ *Metastasis***:** Inflammation is linked to the spread of cancer cells to distant sites (metastasis). Inflammatory factors can help cancer cells invade surrounding tissues and enter the bloodstream, facilitating their dissemination to other parts of the body.

It's important to note that while inflammation contributes to the development and progression of both metabolic syndrome and breast cancer, these conditions are influenced by a complex interplay of factors (36).

Hormonal imbalance and its connection to metabolic syndrome and breast cancer

Hormonal imbalances, particularly involving estrogen and progesterone, have long been associated with breast cancer. Obesity, a common feature of metabolic syndrome, is associated with increased estrogen production, leading to higher estrogen levels in the body. In addition to estrogen, insulin-like growth factor 1 (IGF-1) has also been implicated in breast cancer development. Elevated insulin levels, as seen in insulin resistance, can lead to increased production of IGF-1, which can promote the growth of breast cancer cells. The interaction between hormonal imbalances, metabolic syndrome, and breast cancer is complex and requires further research to fully understand (37-39).

Lifestyle changes to reduce the risk of metabolic syndrome and breast cancer

This relationship might be due to hormonal changes associated with excess adipose tissue, particularly in postmenopausal women. Higher levels of estrogen produced by adipose tissue can contribute to the development of hormone-sensitive breast cancers. Additionally, obesity is linked to chronic inflammation, which can also play a role in cancer development. While BMI (Body Mass Index) is a commonly used metric to assess obesity, it doesn't provide information about body composition. Waist circumference (WC) and waist-to-hip ratio (WHR) are considered more informative measures of body fat distribution. Abdominal obesity, as indicated by an increased WC or WHR, has been associated with a higher risk of metabolic syndrome and certain types of cancer, including breast cancer. Higher BMI levels, especially BMI $\geq$ 30 kg/m^2 (indicating obesity), have been linked to larger tumors, poorer tumor differentiation (which is related to how aggressive the cancer cells look under a microscope), a greater likelihood of lymph node involvement (indicating more advanced disease), and generally worse prognosis in breast cancer patients. Adopting a healthy diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats can indeed promote weight loss, improve insulin sensitivity, and contribute to overall health. Such a diet is associated with lower levels of inflammation, improved metabolic health, and reduced risk of chronic diseases, including metabolic syndrome and certain types of cancer. It's important to note that while lifestyle changes can contribute to reducing the risk of metabolic syndrome and breast cancer, they are just one aspect of a

comprehensive approach to health. Regular physical activity, such as aerobic exercises and strength training, can also help manage weight, improve cardiovascular health, and reduce the risk of metabolic syndrome and breast cancer. Avoiding tobacco products and limiting alcohol consumption are also important lifestyle changes to reduce the risk of both metabolic syndrome and breast cancer. Quitting smoking can improve lung health, reduce the risk of cardiovascular diseases, and decrease the risk of certain types of cancer (40-43).

Screening and early detection of breast cancer in individuals with metabolic syndrome

Regular breast cancer screening is crucial for early detection and improved outcomes. Mammography is the most common screening tool for breast cancer, and guidelines recommend regular screenings starting at age 40 or earlier for women with certain risk factors. Women with metabolic syndrome may have additional risk factors, such as obesity and hormonal imbalances, which should be considered when determining the frequency and timing of screenings. In addition to mammography, other imaging modalities, such as ultrasound and magnetic resonance imaging (MRI), may be used in specific cases or for high-risk individuals. Breast self-exams and clinical breast exams by healthcare professionals are also important components of breast cancer screening. Early detection allows for timely intervention and increases the chances of successful treatment (44).

The treatment of breast cancer depends on several factors, including the stage of cancer, the type of breast cancer, the presence of specific receptors on the cancer cells, the patient's overall health, and their personal preferences. Breast cancer treatment typically involves a combination of therapies, which may include surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and immunotherapy. Here's a detailed overview of each treatment option:

- ✓ **Surgery:**
  - **Lumpectomy:** This procedure involves removing the tumor along with a small amount of surrounding healthy tissue. It's often used for early-stage breast cancer.
  - **Mastectomy:** This involves the complete removal of the breast tissue. There are different types of mastectomy, including simple or total mastectomy, modified radical mastectomy, and bilateral mastectomy (removal of both breasts).
  - **Sentinel Lymph Node Biopsy:** During surgery, the surgeon may remove a few lymph nodes to check if cancer has spread to the lymph nodes. This helps determine the stage of the cancer.
- ✓ **Radiation Therapy:**
  - After surgery, radiation therapy may be used to destroy any remaining cancer cells and reduce the risk of recurrence. It involves targeted radiation to the breast area.
- ✓ **Chemotherapy:**
  - Chemotherapy uses powerful drugs to kill or slow the growth of cancer cells. It can be administered before or after surgery. It's often used for larger tumors, cancers that have spread to the lymph nodes, or metastatic breast cancer.
- ✓ **Targeted Therapy:**
  - Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. For example, HER2-positive breast cancers can be treated with drugs like trastuzumab (Herceptin) that target the HER2 protein.
- ✓ **Hormone Therapy:**
  - Hormone therapy is used for hormone receptor-positive breast cancers (estrogen receptor or progesterone receptor-positive). Drugs like tamoxifen, aromatase inhibitors (letrozole, anastrozole), and others block hormones that fuel the growth of these cancers.
- ✓ **Immunotherapy:**
  - Immunotherapy stimulates the body's immune system to recognize and attack cancer cells. It's still under research for breast cancer and is more commonly used in other types of cancers.
- ✓ **Clinical Trials:**
  - Clinical trials offer experimental treatments that are being tested for safety and effectiveness. Participation in a clinical trial can provide access to cutting-edge therapies.

✓ **Adjuvant and Neoadjuvant Therapy:**
- Adjuvant therapy is treatment given after surgery to eliminate any remaining cancer cells and reduce the risk of recurrence. Neoadjuvant therapy is given before surgery to shrink tumors and make them easier to remove.

✓ **Palliative Care:**
- Palliative care focuses on providing relief from symptoms and improving the quality of life for patients with advanced or metastatic breast cancer.

Treatment options for individuals with insulin resistance syndrome and malignant breast neoplasm

Medications, such as antihypertensives, statins, and antidiabetic drugs, may be prescribed to control specific conditions. In the case of breast cancer, treatment options depend on various factors, including the stage and subtype of cancer, as well as individual preferences. The goal is to remove or destroy cancer cells, prevent recurrence, and improve overall survival. A multidisciplinary approach, involving oncologists, surgeons, radiologists, and other healthcare professionals, is often used to develop a personalized treatment plan. These factors can increase the risk of various health issues, including cardiovascular diseases and certain types of cancer, including breast cancer. When it comes to breast cancer treatment for individuals with metabolic syndrome, the approach will depend on various factors, such as the stage of cancer, the specific characteristics of the cancer, and the individual's overall health. Treatment options may include:

✓ The extent of surgery will depend on the stage of cancer and other factors.
✓ Radiation therapy uses high-energy rays to target and destroy cancer cells.
✓ Chemotherapy is a systemic treatment that uses drugs to target and eliminate cancer cells.
✓ Hormone receptor-positive breast cancers depend on hormones like estrogen or progesterone to grow.
✓ Targeted therapies are drugs that specifically target certain molecules involved in cancer growth. They are often used for specific types of breast cancer, such as HER2-positive breast cancer.
✓ Immunotherapy is a newer treatment option that helps the immune system recognize and attack cancer cells.
✓ Given the connection between metabolic syndrome and breast cancer, making healthy lifestyle changes is crucial. This may include addressing underlying conditions like diabetes and high blood pressure.

It's important for individuals with both metabolic syndrome and breast cancer to work closely with a medical team that includes oncologists, surgeons, and other specialists. They can develop a comprehensive treatment plan that considers both conditions and their potential interactions (45).

Conclusion

The link between metabolic syndrome and breast cancer is a complex and evolving field of research. While the exact mechanisms connecting the two conditions are still being unraveled, metabolic syndrome increases the risk of breast cancer. Insulin resistance, chronic inflammation, hormonal imbalances, and lifestyle factors all contribute to this increased risk. By understanding these connections, individuals can take proactive steps toward managing metabolic syndrome and reducing the risk of breast cancer. Healthy lifestyle choices, regular screenings, and appropriate treatment strategies can help mitigate the impact of these conditions and promote a healthier future. In summary, the link between breast cancer and metabolic syndrome is an evolving area of research. While there is evidence suggesting an association, more studies are needed to fully understand the underlying mechanisms and to develop targeted prevention and treatment strategies.

Reference

1. Chen, L., Liang, L., Yan, C., Liu, L., & Shu, C. (2017). The Association Between Metabolic Syndrome and Breast Cancer in Chinese Women: A Systematic Review and Meta-Analysis. Oncotarget, 8(10), 16883-16895. https://doi.org/10.18632/oncotarget.15232

2. Xiang, Y. Z., Xie, Q., Cheng, Y., Li, Y. J., & Ge, W. P. (2017). Metabolic Syndrome and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies. Oncotarget, 8(43), 75384-75395. https://doi.org/10.18632/oncotarget.20280
3. Iacoviello, L., Bonaccio, M., de Gaetano, G. and Donati, M.B., 2021, July. Epidemiology of breast cancer, a paradigm of the "common soil" hypothesis. In *Seminars in cancer biology* (Vol. 72, pp. 4-10). Academic Press.
4. Kumar, N.B., Lyman, G.H., Allen, K., Cox, C.E. and Schapira, D.V., 1995. Timing of weight gain and breast cancer risk. *Cancer*, *76*(2), pp.243-249.
5. Buono, G., Crispo, A., Giuliano, M., De Angelis, C., Schettini, F., Forestieri, V., Lauria, R., De Laurentiis, M., De Placido, P., Rea, C.G. and Pacilio, C., 2020. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. *Breast cancer research and treatment*, *182*, pp.401-409.
6. Maiti, B., Kundranda, M.N., Spiro, T.P. and Daw, H.A., 2010. The association of metabolic syndrome with triple-negative breast cancer. *Breast cancer research and treatment*, *121*, pp.479-483.
7. Kabat, G.C., Kim, M., Chlebowski, R.T., Khandekar, J., Ko, M.G., McTiernan, A., Neuhouser, M.L., Parker, D.R., Shikany, J.M., Stefanick, M.L. and Thomson, C.A., 2009. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. *Cancer Epidemiology Biomarkers & Prevention*, *18*(7), pp.2046-2053.
8. Kelly, T., Yang, W., Chen, C.S., Reynolds, K. and He, J., 2008. Global burden of obesity in 2005 and projections to 2030. *International journal of obesity*, *32*(9), pp.1431-1437.
9. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, *68*(6), pp.394-424.
10. Dieli-Conwright, C.M., Wong, L., Waliany, S. *et al.* Metabolic syndrome and breast cancer survivors: a follow-up analysis after completion of chemotherapy. *Diabetol Metab Syndr* **14**, 36 (2022). https://doi.org/10.1186/s13098-022-00807-y
11. Nissen, M.J., Shapiro, A. and Swenson, K.K., 2011. Changes in weight and body composition in women receiving chemotherapy for breast cancer. *Clinical breast cancer*, *11*(1), pp.52-60.
12. Gandhi, A., Copson, E., Eccles, D., Durcan, L., Howell, A., Morris, J., Howell, S., McDiarmid, S., Sellers, K., Evans, D.G. and Harvie, M., 2019. Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. *The Breast*, *45*, pp.1-6.
13. Alexopoulos, C.G., Blatsios, B. and Avgerinos, A., 1987. Serum lipids and lipoprotein disorders in cancer patients. *Cancer*, *60*(12), pp.3065-3070.
14. Larsson, S.C., Mantzoros, C.S. and Wolk, A., 2007. Diabetes mellitus and risk of breast cancer: a meta-analysis. *International journal of cancer*, *121*(4), pp.856-862.
15. Goodman, M.T., Cologne, J.B., Moriwaki, H., Vaeth, M. and Mabuchi, K., 1997. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors. *Preventive medicine*, *26*(1), pp.144-153.
16. Jee, S.H., Ohrr, H., Sull, J.W., Yun, J.E., Ji, M. and Samet, J.M., 2005. Fasting serum glucose level and cancer risk in Korean men and women. *Jama*, *293*(2), pp.194-202.
17. Morimoto, L.M., White, E., Chen, Z., Chlebowski, R.T., Hays, J., Kuller, L., Lopez, A.M., Manson, J., Margolis, K.L., Muti, P.C. and Stefanick, M.L., 2002. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). *Cancer Causes & Control*, *13*, pp.741-751.
18. Peacock, S.L., White, E., Daling, J.R., Voigt, L.F. and Malone, K.E., 1999. Relation between obesity and breast cancer in young women. *American journal of epidemiology*, *149*(4), pp.339-346.
19. Agurs-Collins, T., Kim, K.S., Dunston, G.M. and Adams-Campbell, L.L., 1998. Plasma lipid alterations in African-American women with breast cancer. *Journal of cancer research and clinical oncology*, *124*, pp.186-190.

20. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012; 36: 141–147. doi: 10.1016/j.canep.2011.03.007 PMID: 21890443
21. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012; 130: 921–929. doi: 10.1002/ijc.26071 PMID: 21413010
22. Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res. 1995; 6: 449–456. PMID: 8817689
23. Norat T, Dossus L, Rinaldi S, Overvad K, Gronbaek H, Tjonneland A, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr. 2007; 61: 91–98. PMID: 16900085
24. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011; 7: 1003–1015. PMID: 21912508
25. Bradley LM, Gierthy JF, Pentecost BT. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line. J Steroid Biochem Mol Biol. 2008; 109: 185–196. doi: 10.1016/j.jsbmb.2007.10.006 PMID: 18337089
26. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control. 2004; 15: 267–275. PMID: 15090721
27. Strange KS, Wilkinson D, Edin G, Emerman JT. Mitogenic properties of insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and epidermal growth factor on human breast stromal cells in primary culture. Breast Cancer Res Treat. 2004; 84: 77–84. PMID: 14999138
28. Sachdev D and Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8: 197–209. PMID: 11566611
29. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999; 6: 165–173. PMID: 10731105
30. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995; 87: 190–197. PMID: 7707406
31. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005; 12: 1071–1082. PMID: 16322344
32. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999; 20: 535–582. PMID: 10453357
33. Nelson LR and Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001; 45: S116–S124. PMID: 11511861
34. McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM, Kumar S. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord. 2000; 24: 875–881. PMID: 10918534
35. Sherif K, Kushner H, Falkner BE. Sex hormone-binding globulin and insulin resistance in African-American women. Metabolism. 1998; 47: 70–74. PMID: 9440480
36. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in AfricanAmerican and white American women. Endocr Rev. 2007; 28: 763–777. PMID: 17981890
37. Sieminska L, Wojciechowska C, Foltyn W, Kajdaniuk D, Kos-Kudla B, Marek B, et al. The relation of serum adiponectin and leptin levels to metabolic syndrome in women before and after the menopause. Endokrynol Pol. 2006; 57: 15–22. PMID: 16575758
38. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002; 4: 65–69. PMID: 11879566

39. Vona-Davis L and Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14: 189–206. PMID: 17639037
40. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004; 68: 975–981. PMID: 15502375
41. Beaulieu LM, Whitley BR, Wiesner TF, Rehault SM, Palmieri D, Elkahloun AG, et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays. 2007; 29: 1029–1038. PMID: 17876797
42. Iacoviello L, Agnoli C, De Curtis A, di Castelnuovo A, Giurdanella MC, Krogh V, et al. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study. BMJ Open. 2013; 3: e003725. doi: 10.1136/bmjopen-2013-003725 PMID: 24231461
43. Nestler JE. Insulin regulation of human ovarian androgens. Hum Reprod. 1997; 12 Suppl 1: 53–62. PMID: 9403321
44. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst. 1996; 88: 756–758. PMID: 8637031
45. Al Delaimy WK, Jansen EH, Peeters PH, van der Laan JD, van Noord PA, Boshuizen HC, et al. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers. 2006; 11: 370–382. PMID: 16908443